VANCOUVER, British Columbia, Aug. 31, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and six months ended June 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Business Highlights: […]
Other News
Biotricity Provides Quarter Update and Announces Continued Growth
Technology Revenues Surged in the Quarter Ended June 30, 2020 REDWOOD CITY, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced record results in its technology service revenues, demonstrating a continued pattern of improved growth for its first […]
Ontrak Announces NASDAQ Global Market Listing
SANTA MONICA, Calif.–(BUSINESS WIRE)–Ontrak, Inc. (NASDAQ: OTRK) (“Ontrak” or the “Company”), a leading AI-powered and telehealth enabled, virtualized outpatient healthcare treatment company, today announced that the company’s Common Stock has been listed on the NASDAQ Global Market. Ontrak shares will continue to trade under the ticker “OTRK.” Mr. Terren Peizer, the Company’s […]
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates, ARO-APOC3 targeting apolipoprotein C-III (APOC3) being developed as a treatment for patients with hypertriglyceridemia, and ARO-ANG3 targeting angiopoietin like protein 3 (ANGPTL3) being developed as a treatment […]
Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
HELP Study results, evaluating levosimendan in patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF), will be presented during a Late-Breaking Clinical Trial session during the HFSA Annual Scientific Meeting MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing […]
Biome Analytics Appoints Michael Thompson President
Medical device and analytics veteran brings 15 years of senior leadership experience and a proven track record of value creation SAN FRANCISCO–(BUSINESS WIRE)–Biome Analytics, the leading cardiovascular performance company, today announced the appointment of Michael Thompson as President, effective September 8, 2020. Thompson will assume day to day operational responsibility […]
Veryan Launches BioMimics 3D Vascular Stent System in the US
Press release Horsham, UK 01 September 2020 Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly- differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including […]
Philips expands its dedicated cardiovascular ultrasound offering by launching Affiniti CVx for increased productivity
Philips introduces Affiniti CVx and Release 7.0 of EPIQ CVx with breakthrough interventional and productivity features to support cardiology departments managing everyday challenges Philips debuts impactful solutions in cardiology at ESC 2020 (Aug 29 – Sept 1) Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health […]
Matinas BioPharma Completes Enrollment of ENHANCE-IT Study of MAT9001 Against Vascepa®
Topline data expected first quarter 2021 BEDMINSTER, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has completed enrollment in the ENHANCE-IT Study (Pharmacodynamic Effects of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids to ENHANCE Efficacy in Adults with Hypertriglyceridemia), a […]
NILEMDO® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering treatment that significantly reduces LDL-C on top of statins and other lipid-lowering therapies1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver1 Due to its unique mechanism of action, bempedoic […]
Recent
Nyra Medical Receives Prestigious Jon DeHaan Foundation Award for Innovation in Cardiology at EuroPCR 2026
AHN’s Allegheny General Hospital Unveils New, State-of-the-Art Cardiac Cath and Electrophysiology Labs, following Completion of $19 Million Renovation Project
egnite Expands Medical Advisory Board with Three Nationally Recognized Cardiovascular Specialists
Popular
- No commented posts yet